COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Observational Study of Meloxicam in Any Labeled Indication

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02182739
Recruitment Status : Completed
First Posted : July 8, 2014
Last Update Posted : October 29, 2014
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
Evaluation on the amelioration of symptom intensity of the indication and to evaluate drug tolerability.

Condition or disease Intervention/treatment
Arthritis, Rheumatoid Drug: Meloxicam

Layout table for study information
Study Type : Observational
Actual Enrollment : 13039 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Programa de Experiencia Therapéutica Personalizada (Personalized Therapeutic Experience Program)
Study Start Date : January 2001
Actual Primary Completion Date : December 2001

Resource links provided by the National Library of Medicine

Drug Information available for: Meloxicam

Group/Cohort Intervention/treatment
Meloxicam Drug: Meloxicam
tablets or injectable solution

Primary Outcome Measures :
  1. Change in assessment of intensity of pain on a 4-point verbal rating scale [ Time Frame: up to 1 year ]
  2. Assessment of tolerability on a 4-point scale [ Time Frame: up to 1 year ]

Secondary Outcome Measures :
  1. Number of patients with adverse events [ Time Frame: up to 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
primary care

Inclusion Criteria:

  • Patients according to the physicians medical criteria on the labeled indications for Meloxicam

Exclusion Criteria:

  • none

Additional Information:
Layout table for additonal information
Responsible Party: Boehringer Ingelheim Identifier: NCT02182739    
Other Study ID Numbers: 107.249
First Posted: July 8, 2014    Key Record Dates
Last Update Posted: October 29, 2014
Last Verified: July 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action